Galera Therapeutics, Inc. Common Stock
GRTX
GRTX was delisted on the 3rd of June, 2024.
40 hedge funds and large institutions have $54.4M invested in Galera Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 5 closing their positions.
9,635% more call options, than puts
Call options by funds: $8.37M | Put options by funds: $86K
205% more capital invested
Capital invested by funds: $17.9M → $54.4M (+$36.6M)
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
25% more funds holding
Funds holding: 32 → 40 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$5.89M |
| 2 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$2.06M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$1.47M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.13M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$1.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$206K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$72.2K |
| 3 |
HSBC Holdings
London,
United Kingdom
|
-$17.9K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$15.2K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$7.04K |
GRTX Hedge Fund Activity: Q1 2023 in Review
40 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Galera Therapeutics, Inc. Common Stock (GRTX) for Q1 2023, worth a combined $54.4M — up 205% from $17.9M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new GRTX positions and 5 closed out — a net gain of 8 holders — while 12 added to existing stakes and 5 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $5.89M. The largest seller was Bridgeway Capital Management, cutting an estimated $206K.
- 40 institutional investors held Galera Therapeutics, Inc. Common Stock (GRTX) as of Q1 2023, up from 32 in Q4 2022.
- Funds reported $54.4M of Galera Therapeutics, Inc. Common Stock stock for Q1 2023, up 205% quarter-over-quarter.
- 13 funds opened new Galera Therapeutics, Inc. Common Stock positions in Q1 2023 and 5 closed out, a net change of +8 holders.
- The largest Galera Therapeutics, Inc. Common Stock buyer in Q1 2023 was Alyeska Investment Group, an estimated $5.89M added.
- The largest Galera Therapeutics, Inc. Common Stock seller in Q1 2023 was Bridgeway Capital Management, an estimated $206K sold.
Based on aggregated 13F filings for Q1 2023.